CJC-1295 / Ipamorelin

Growth hormone secretagogue combination supporting GH pulsatility.

Overview

CJC-1295 is a synthetic GHRH analog. Ipamorelin is a synthetic GHRP acting as a ghrelin receptor agonist. Together they stimulate pituitary GH release through two complementary pathways. Both are compounded peptides, not FDA-approved medications. This combination is assessed in the context of a full hormone panel.

Mechanism

CJC-1295 prolongs GHRH activity. Ipamorelin stimulates GH release via the ghrelin receptor without significantly affecting cortisol or prolactin at standard doses. Clinical outcome depends on baseline GH axis function and is individual.

Clinical Considerations

• Assessed as part of a full hormone panel — not prescribed as a standalone.
• Commonly reported: improved sleep quality, water retention, tingling in extremities early in use.
• Requires IGF-1 and hormone panel review.

Potential Side Effects

• Water retention, particularly in the first 2–4 weeks — common with GH optimization protocols.
• Tingling or numbness in the extremities (carpal tunnel-like sensation) — typically resolves with dose adjustment.
• Mild headache or flushing immediately following injection.
• Potential for blood glucose changes — discuss monitoring with your provider if metabolic conditions are present.

All prescriptions require a telehealth consultation with a licensed provider. A prescription is not guaranteed. Individual results vary. Not FDA-approved unless noted otherwise.